Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A phase 2/3 trial testing Zanzalintinib in neuroendocrine tumours, now recruiting.
Overview
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours is a phase 2/3 interventional study registered as NCT06943755, led by Exelixis, and recruiting when checked on 2026-09-11. Official title: A Phase 2/3, Multicenter, Randomised Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumours. Planned enrolment is 440 participants (estimated). The study started in 2025-07-21 and primary completion is expected in 2029-06-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shares Exelixis, Zanzalintinib and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Shares Zanzalintinib and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Shares Zanzalintinib and the tag ctgov-ingest.
- TreatmentPeluntamig
Shares Neuroendocrine tumours and the tag ctgov-ingest.
- TreatmentZG006
Shares Neuroendocrine tumours and the tag ctgov-ingest.
- TreatmentPM8002
Shares Neuroendocrine tumours and the tag ctgov-ingest.
- TreatmentCabozantinib
Shares Exelixis, Neuroendocrine tumours.